U.S. Markets close in 5 hrs 7 mins

Mylan's Stock Is No Longer A Buy According To Analysts At Argus

Jayson Derrick

Analysts at Argus no longer hold a bullish view on Mylan N.V. (NASDAQ: MYL) after the company cut its full-year guidance and cautioned that its earnings per share will decline in 2017. The firm's Jasper Hellweg downgraded Mylan's stock rating from Buy to Hold as the stock is fairly valued at its current price of near $30 per share.

Mylan's stock has been under pressure over the past year and this weakness attracted the attention of activist investors who are looking to influence the company and reverse the weakness, Hellweg commented in a research report. While this is typically seen as a positive catalyst for the stock there are bigger issues at play that could limit upside.

On top of Mylan's revised outlook to the downside, the pharmaceutical company also has to contend with unfavorable regulatory developments, pricing pressures, and heightened competition, Hellweg continued. In fact, the core EpiPen product now faces new competition from Adamis Pharmaceuticals Corp (NASDAQ: ADMP)'s Symjepi epinephrine syringe, which received FDA approval on June 15 and will be labeled as a low-cost alternative to the Epi-Pen.

Adamis is also developing a "junior version" of Symjepi, which will also compete with Mylan's low-dose EpiPen Jr.

On top of that, Mylan is under investigation by the New York attorney general for selling EpiPens to schools in exchange for exclusive contracts. Also, Sanofi SA (ADR) (NYSE: SNY) filed an antitrust lawsuit against Mylan and alleges the company is unfairly offering discounts to insurers and pharmacy benefit managers.

Related Links:

The Prescription For Generic Drugs ETF

Mylan Price Target Slashed Even As TLD Drug Receives Tentative Approval
________
Image Credit: By Intropin - Own work, CC BY 3.0, via Wikimedia Commons

Latest Ratings for MYL

Date Firm Action From To
Aug 2017 Argus Downgrades Buy Hold
Aug 2017 Citigroup Upgrades Neutral Buy
Aug 2017 Morgan Stanley Maintains Equal-Weight

View More Analyst Ratings for MYL
View the Latest Analyst Ratings

See more from Benzinga

© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.